| Identification | Back Directory | [Name]
GFT505 | [CAS]
824932-88-9 | [Synonyms]
GFT505
elafibranor
2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid
Propanoic acid, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl- | [Molecular Formula]
C22H24O4S | [MDL Number]
MFCD27987940 | [MOL File]
824932-88-9.mol | [Molecular Weight]
384.49 |
| Chemical Properties | Back Directory | [Melting point ]
140-144°C | [Boiling point ]
569.0±50.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [storage temp. ]
Amber Vial, -20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
3.34±0.11(Predicted) | [color ]
Yellow | [Stability:]
Light Sensitive |
| Hazard Information | Back Directory | [Uses]
GFT-505 is a?dual?PPARα/δ agonist. Studies have shown that GFT-505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. It may also be a potential new drug candidate for treating lipid and glucose disorders. |
|
|